The COST Action CA17140 entitled “Nano2Clinic: Cancer Nanomedicine – from the bench to the bedside” focuses on the development of nanosystems transporting anti-cancer drugs. The pan-European network of specialists from universities, research centers, clinical research organizations and companies is involved in the design of these nanosystems, their preclinical evaluation, the investigation of their pharmacokinetics and toxicity, as well as the preparation and approval of protocols for Phase I clinical studies in patients.